NZ540435A

NZ540435A - Rapidly disintegrating dosage form for releasing nicotine in the oral cavity or in body cavities

Info

Publication number: NZ540435A
Application number: NZ540435A
Authority: NZ
Inventors: Wolfgang Laux; Markus Krumee; Flakenhausen Christian Von
Original assignee: Lohmann Therapie Syst Lts
Priority date: 2000-07-04
Filing date: 2001-06-22
Publication date: 2008-07-31
Also published as: JP2004501958A; US8313769B2; PL366313A1; IL153716A0; EP1296661B1; KR20030041950A; ATE484277T1; HUP0301410A2; RU2356533C2; EP1588701A3; RU2005114465A; RU2297213C2; BR0112495A; US7988997B2; AR029562A1; ZA200300316B; DE50115660D1; DE10032456A1; KR100709136B1; JP4870386B2

Abstract

Disclosed is a dosage form that rapidly disintegrates or is soluble in an aqueous environment, for rapid release of the active substance nicotine, in the oral cavity, in a body orifice or in a body cavity of an animal, including a human, wherein said dosage form comprises a matrix which contains one or more water-soluble polymers as base substances, and the active ingredient nicotine, said dosage form is characterized in that it is provided with spaces or cavities that are present in the polymeric matrix and whose contents differ from the matrix in terms of the state of aggregation, and wherein said dosage form does not contain a foam-stabilizing agent. Also disclosed are processes for production of the dosage forms.

Description

New Zealand Paient Spedficaiion for Paient Number 540435 540435 l • " RAPIDLY DISINTEGRATING DOSAGE FORM FOR RELEASING NICOTINE IN THE ORAL CAVITY OR IN BODY CAVITIES The invention relates to preferably sheet-like dosage forms which rapidly disintegrate in an aqueous environment, in particular oral dosage forms, which make possible rapid release of nicotine in the oral cavity or in other body orifices or body cavities and which have a matrix based on water-soluble polymers as base substances. The invention relates in particular to dosage forms of the type mentioned which are in the form of wafers. The invention also includes processes for the production of such dosage forms.

Pharmaceutical dosage forms, e.g. buccal or sublingual tablets, which release active ingredients in the oral cavity, which are then absorbed through the oral mucosa are advantageous in many respects. They facilitate oral administration of medicaments to certain patients who have difficulty in taking other oral drug forms—e.g. because of problems with swallowing. Since absorption via the oral mucosa avoids passage through the gastrointestinal tract, a rapid onset of action and extensive utilization of active ingredient are ensured. The advantages also apply to vaginal, rectal and intranasal administration forms.

Suitable oral drug forms v/hich have the aforementioned properties are, beside sublingual or buccal tablets, also sheet-like, wafer-like dosage forms (called wafers). Because their thickness is low and they are capable of rapid disintegration or dissolution they are distinguished in particular by rapid release of medicaments and other active ingredients in the oral cavity. Such wafer-like drug forms are usually composed of film-forming, water-soluble polymers such as, for example, certain cellulose derivatives. On contact with water or saliva, the polymers dissolve and the drug form disintegrates, releasing the active ingredients present therein. The onset and the time course of release of active ingredient depend to a great extent on the thickness of the drug form (of the wafer); the thinner it is, the more rapidly disintegration progresses in an aqueous environment, because the solvent can penetrate faster into the inner regions of the drug form. On the other hand, such drug forms (wafers) must have a certain thickness in order to be able to comply with their intended function, namely to deliver active ingredients. Consequently, the thickness of such dosage forms is essentially determined by the nature and amount of the active ingredient which they contain and are intended to 3 0 MAY 2005 2 release. As the thickness increases, the disintegration or dissolution of the wafer becomes correspondingly slower. Thicker wafers in particular, but also those with a relatively low thickness, are prone, because of their sheet-like, smooth shape and the retarded disintegration, to stick and become firmly adherent to the roof of the mouth or 5 other surfaces of the oral mucosa. This is caused by the polymer layers dissolving on the surface, which form a tacky and viscid film.

The property of these drug forms of becoming firmly adherent to the roof of the mouth and other surfaces of the oral mucosa may cause an unpleasant sensation for the relevant person or for the patient, i.e. the mouthfeel caused by these wafers is unpleasant or 10 upsetting and therefore in need of improvement.

EP 0 450 141 B2 discloses a carrier material for the administration of drugs which rapidly dissolve on contact with saliva after oral intake. This carrier material has a porous dehydrated skeletal structure and is based, in particular, on proteins and polysaccharides. The cavities produced by dehydration are used for incorporation of 15 liquid active substances. The gelatin/polysaccharide carriers described can also be used in the form of wafers. No measures are provided for reducing the tendency to stick; this risk does exist, however, because the dehydrated carrier materials are rehydrated on contact with saliva at the latest and thus acquire a tacky surface.

It was therefore the object of the present invention to provide a dosage form, which 20 overcomes, or ameliorates, or provides an alternative, to previously provided dosage forms.

One aspect of the invention concerns a dosage form that rapidly disintegrates or is soluble in an aqueous environment, for rapid release of the active substance nicotine, in the oral cavity, in a body orifice or in a body cavity of an animal, including a human, 25 wherein the dosage form comprises a matrix which contains one or more water-soluble polymers as base substances, and the active ingredient nicotine, and wherein the dosage form is characterized in that it is provided with spaces or cavities that are present in the polymeric matrix and whose contents differ from the matrix in terms of the state of aggregation. 3 Another form of the invention concerns various processes for preparing the dosage form.

The active ingredient used in the dosage form is nicotine, and as used here, the term "active ingredient", unless otherwise specified, refers to nicotine or its salts, or to other 5 pharmaceutical^ or veterinarially acceptable forms of nicotine, as both naturally occurring or synthesized forms, or chemically transformed but retaining nicotine's physiological activity.

In particular, the spaces or cavities may have gaseous or liquid contents, while the polymer matrix itself has a solid or semisolid state of aggregation. The dosage forms of 10 the invention thus have spatial regions with different phases; the spaces or cavities represent a second phase which may be present in the interior of the polymer matrix (first phase), but it may also extend as far as the outer edge.

On the one hand, the spaces or cavities of the invention facilitate access of water or saliva or other body fluids into the interior of the dosage form (e.g. wafer) and thus 15 speed up the dissolution of the dosage form and the release of active ingredient, which represents an advantage in particular with thicker dosage forms (wafers). On the other hand, the thickness of the walls of the spaces or cavities is low because they represent, for example, solidified bubbles, so that a rapid dissolution or disintegration of these cavities takes place. This alters the internal structure and, as a consequence, also the 20 surface of the dosage form, so that the surface becomes irregular. For example, the surface thus acquires a corrugated structure or irregularities. This and the stiffness of the product prevent the wafer sticking to the oral mucosa. Because the tendency to stick is reduced, the dosage forms of the invention are distinguished by an improved mouthfeel, which eventually leads to improved acceptance by the users or patients.

The residence time of the dosage forms of the invention at the site of administration (e.g. oral cavity) or the disintegration time is preferably in the range from 1 s to 5 min, more preferably in the range from 5 s to 1 min, and most preferably in the range from 10 s to 30 s.

The invention is not, however, confined to oral dosage forms which release active 30 ingredients in the region of the oral cavity. On the contrary, it also extends to dosage 4 forms which are introduced into other body cavities or body orifices and release their active ingredients there, for example rectal, vaginal or intranasal dosage forms. The released active ingredient is either absorbed at the site of administration, e.g. through the oral mucosa, or it is transported further and absorbed at another site (e.g. in the 5 gastrointestinal tract after the active ingredient released in the oral cavity has been swallowed).

The spaces or cavities of the dosage form may each be present isolated from one another in the polymeric matrix or preferably in the form of solidified bubbles. Another embodiment provides for the spaces or cavities to be connected to one another, 10 preferably forming a connected channel system penetrating through the matrix.

Suitable dosage forms having the spaces or cavities of the invention are, in particular, polymeric materials which represent solidified foams.

The spaces or cavities are preferably filled with gas or a gas mixture, in particular air; however, it may also be advantageous for them to contain other gases or gas mixtures. 15 A further embodiment provides for the spaces or cavities to be filled with a liquid or a liquid mixture (for example oils), these liquids not being miscible with the matrix material and not dissolving the polymeric framework. The liquid or the liquid mixture may additionally comprise one or more active pharmaceutical ingredients.

The total volume of the spaces or cavities, as a proportion of the total volume of the 20 dosage form, is preferably from 5 to 98%, with preference for 50-80%. In this way the intended adhesion-diminishing effect is achieved without impairing too greatly the capacity of the dosage form to take up active ingredient. Another important parameter influencing the properties of the dosage forms of the invention is the diameter of the cavities or bubbles. The bubbles or cavities are preferably produced using a foam-25 beating machine. It is thus possible to adjust the diameter of the bubbles in a wide range almost as desired. Thus, the diameter of the bubbles or cavities can be in the rang from 0.01 to 50 |j.m; diameters between 0.1 and 10 (j,m are particularly preferred.

The cavities of the dosage forms of the invention are preferably free of active ingredient; however, it may be advantageous for these cavities to contain excipients or 30 additives, preferably surfactants or gas-forming substances.

In order to diminish further the tendency of the dosage forms to stick it is possible additionally to make use of the measure of giving the surfaces of the dosage form an uneven or irregular shape, preferably corrugated or like a relief or with a structured surface. Such an irregular surface structure can be caused, for example, by the bubble-5 like cavities introduced into the polymer matrix and/or by a subsequent special drying treatment.

The matrix of the dosage forms of the invention comprises as base substances a water-soluble polymer or mixtures of such polymers. Preferably used for this purpose are synthetic or partially synthetic polymers or biopolymers of natural origin, which are 10 film-forming and water-soluble and/or which are suitable for foam formation. Particularly suitable polymers are those preferably selected from the group comprising cellulose derivatives, polyvinyl alcohol, polyacrylates and polyvinylpyrrolidone. Particularly preferred cellulose derivatives are hydroxypropylmethylcellulose, carboxymethylcellulose, hydroxypropylcellulose, hydroxymethylcellulose, 15 methylcellulose, and other substituted cellulose derivatives. Likewise preferred are water-soluble polysaccharides of vegetable, microbial or synthetic origin, in particular those polysaccharides which are not cellulose derivatives, such as, for example, pullulan, xanthan, alginates, dextrans, agar-agar, pectins and carrageenan; the last-mentioned is particularly preferred. Also suitable are proteins, preferably gelatin or 20 other gel-forming proteins, and protein hydrolyzates. Suitable protein hydrolyzates include, inter alia, caseinate, whey and vegetable proteins, gelatin and (egg) albumin, and mixtures thereof.

Preferred proteins are caseinates derived from spray-dried dairy products.

The dosage forms of the invention are preferably thin, e.g. in the form of a wafer. The 25 thickness of the dosage form is preferably between 0.1 and 5 mm, particularly preferably between 0.5 and 1 mm. The lower limit for the thickness of the dosage forms is about 50 jxm.

The active ingredient of the invention is nicotine, and its salts and derivatives, especially the pharmaceutically and veterinarially acceptable salts. A preferred salt is 30 nicotine bitartrate (also known as nicotine bitartrate dihydrate, or as nicotine hydrogen tartrate). 6 Additional active ingredients may also be present, especially therapeutically active compounds (without restriction). These may be derived from the following groups: agents for treating infections; virostatics; analgesics such as fentanyl, sufentanil, buprenorphine; anesthetics, anorectics; active ingredients for treating arthritis and 5 asthma, such as terbutaline; anticonvulsants; antidepressants; antidiabetics; antihistamines; antidiarrheals; agents for migraine, pruritus, nausea and retching; travel and sea sickness, such as scopolamine and ondansetron; anti-parkinson agents; antipsychotics; antipyretics, spasmolytics, anticholinergics, anti-ulcer agents such as ranitidine, sympathomimetics; calcium channel blockers such as nifedipine; beta blockers; beta agonists such dobutamine; antiarrhythmics; antihypertensives such as atenolol; ACE inhibitors such as enalapril; benzodiazepine agonists such as flumazenil; coronary, peripheral and cerebral vasodilators; stimulants for the central nervous system; hormones; hypnotics; immunosuppressants; muscle-relaxing agents; parasympatholytics; parasympathomimetics; prostaglandins; proteins, peptides; psychostimulants; sedatives; tranquilizers.

Suitable active ingredients for administration in the mouth or onto the oral mucosa are in principle all those able to undergo buccal and/or gastrointestinal absorption.

The active ingredient content per dose unit is up to 50 mg, preferably up to 30 mg, particularly preferably up to 20 mg.

Further suitable active ingredients are: polishers, abrasives such as titanium dioxide, silicon dioxide etc.; sodium fluoride, dicalcium phosphate; essential oils such as aniseed oil, fennel oil, eucalyptus oil, peppermint oil, spearmint oil, orange oil, sage oil, thyme oil, lemon oil etc.; aromatizers such as camphor, cineol, eucalyptol, menthol, pinene, cinnamaldehyde, cinnamic acid, etc.; honey, citric acid, vitamins, antioxidants, sorbitol.

The dosage forms of the invention are thus also suitable for cosmetic applications and for uses in the areas of dental care, tooth cleaning, oral hygiene or dental hygiene.

Further aromatizers which can be added are vanilla flavor, orange flavor, orange zest flavor, strawberry flavor, raspberry flavor or chocolate flavor, each singly or in combination. It is additionally possible to add one or more sweeteners such as sucralose, aspartame, cyclamate, saccharin and acesulfame, and salts thereof. 7 Suitable excipients are, inter alia, substances from the following group: carboxymethylcelluose, gum arabic, methylcellulose, pectins, modified and unmodified starches, gelatin, animal and/or vegetable proteins, egg albumin, alginates, Brij (an emulsifier), isopropanol, benzyl alcohol, ethyl acetate, ethyl citrate, octyl gallate, 1,2-5 propylene glycol, magnesium stearate, stearic acid, microcrystalline cellulose, Aerosil, lecithin, Tween, propyl gallate, amylogam.

It is additionally possible to dissolve a sugar (or a mixture of sugars) or another carbohydrate material in the foam. The sugar or the carbohydrate increases the mass which the foam has after drying. In addition, the drying and the crystallization of the 10 sugar or of another carbohydrate confers on the dried foam an additional strength and stability. The sugar or other carbohydrates may result in the dried foam having a sweet taste or may improve the organoleptic properties of the foam in other ways. Examples of sugars which can be used for this purpose are, inter alia, maltose, lactose, sucrose, dextrose (glucose) and trehalose, and sugar alcohols such as, for example, mannitol, 15 sorbitol, xylitol, maltitol, and the like. Examples of other suitable carbohydrates are maltodextrin, starch sugar syrup (from corn), soluble starches and the like.

During production of the dosage forms of the invention it is additionally possible to admix one or more acids in order to confer on the foam a pleasant acidic taste. Examples of such acids include, inter alia, citric acid, lactic acid, acetic acid, benzoic 20 acid, propionic acid, oxalic acid, malonic acid, succinic acid, malic acid and tartaric acid. The addition of acid(s) may additionally be necessary or desired in order to reduce the pH of the foam. This is desired in particular when the active ingredient present in the dosage form is relatively insoluble under basic conditions, such as, for example, ibuprofen, or with active ingredients which are unstable under basic conditions.

A further possibility is to add moisturizers or humectants to the dosage forms of the invention, in particular foams, in order to improve the esthetic properties of the dried foam and in order to reduce the fragility or brittleness of the dried foam. Examples of such agents are, inter alia, glycerol, propylene glycol and polyglycerol esters. It is also possible to add, before or after the drying, surface-active substances in order to improve 30 the stability of the foam before or after the drying. Examples of suitable surface-active 8 substances are, inter alia, substituted sorbitan derivatives, in particular those of the Tween series (ICI).

The following processes are proposed for the production of the dosage forms of the invention with improved mouthfeel and reduced tendency to stick.

Firstly a solution or dispersion which comprises at least one water-soluble film-forming polymer and at least one active ingredient is prepared. This solution or dispersion, which may also be a concentrated solution or viscous composition, is subsequently foamed by introducing gas or gas mixture (e.g. air). This can take place by use of a disperser or of a foam-beating machine, but also by other methods, e.g. using ultrasound. Suitable gases are, in particular, 10 also inert gases such as nitrogen, carbon dioxide or helium, or mixtures thereof.

In order to stabilize the foams or compositions containing air bubbles (or containing gas bubbles) which have been produced in this way, a foam-stabilizing agent may be added before or during the production of foam. Agents suitable for this purpose, e.g. surfactants, are known to the skilled worker. Finally, the composition containing air bubbles or the foam is spread as 15 film or layer on a suitable substrate and is then dried. Removal of solvent during the drying causes the foam to solidify to an aerogel, during which the cavities which have formed acquire a permanent structure. Wafers with desired surface dimensions or geometric shapes are obtained by pouring the foamed coating composition into appropriate molds or by punching the individual wafers out of a larger-area piece. The active ingredient-containing drug forms 20 obtained in this way have the properties and advantages of the invention. The shape, number and size of the spaces or cavities produced can be influenced by various process parameters, e.g. by the nature and concentration of the pqlymers, by the viscosity of the polymer composition, by the control of the foaming process, by the selection of the foam-stabilizing agents etc.

Another process of the invention for producing the dosage forms provides, as a modification of the process described above, for a formation of the spaces or cavities in the interior of the polymer matrix to take place by introducing a hydrophobic solvent which is immisciUe with the solvent used to prepare the solution or dispersion. INTELLECTUAL PROPERTY OFFICE OF N.Z. 0 4 jan 2006 received 9 In this case, an emulsion which contains the hydrophobic solvent in the form of finely distributed droplets is produced. Removal of the solvents during the subsequent drying leaves droplet- or bubble-shaped cavities behind in the polymer matrix. In the case of a two-phase system, the solvent of the internal phase must be removed first.

A further possibility in a modification of the process described above is to produce the cavities in such a way that excipients which form a gas or gases are added to the polymer- and active ingredient-containing solution or dispersion, whereby the composition is foamed. This foaming through evolution of gas can take place either during the production of the polymer composition or during the coating of this 10 composition onto the substrate, or not until the subsequent drying process. Substances or mixtures of substances suitable for gas formation are known to the skilled worker. The foaming can also be brought about by decompression of a previously dissolved gas. It is possible to use as gas in particular an inert gas such as nitrogen, carbon dioxide or helium, or a mixture thereof.

Production of the dosage forms of the invention may alternatively also start from a melt of the matrix polymer or polymer mixture. The processing is in principle similar to that with hot melt coating compositions known in the prior art.

Gas or a gas mixture is introduced by one of the aforementioned methods into the polymer melt in order to cause foaming of the melt. The melt is then spread or extruded 20 onto a suitable substrate or poured into a mold and then left to cool and solidify. Processing from the melt is unsuitable if the intended active ingredient is unstable or volatile at the melting point of the polymer melt. It is possible if necessary to add excipients to reduce the melting point of the polymer melt. It is also possible in principle to use hot melt coating compositions known from the prior art as long as they 25 meet the conditions stated in the invention.

In a further modification of the production process described above, the polymer matrix is initially produced in the form of a block. The required sheet-like dosage forms are then removed from the latter by cutting.

Claims

1. 10 The dosage forms of the invention are advantageously suitable for administering medicaments in the oral cavity or for rectal, vaginal or intranasal administration. They can be employed in human medicine and in veterinary medicine. PRODUCTION EXAMPLE 111.43 g of distilled water are introduced; 22.38 g of Mowiol 8-88* are added with stirring;;heating of the mixture to 80° C.;;stirring (30 min);;cooling to 40° C.;;addition of 1.8 g of PEG 400,;addition of 1.8 g of PEG 4000;;homogenization;;addition of aspartame (0.18 g) and flavor (5.58 g);;stirring;;addition of 26.46 g of nicotine hydrogen tartrate;;addition of 1.8 g of silicon dioxide;;stirring (2 h) and foam beating at temperature below 50° C.;;spreading;;drying at 60° C. (15 min).;* partially hydrolyzed polyvinyl alcohol of low viscosity (supplied by Clariant) Received at IPONZ on 29 April 2008 11 THE CLAIMS:

1. A dosage form that rapidly disintegrates or is soluble in an aqueous environment, for rapid release of the active substance nicotine, in the oral cavity, in a body orifice or in a body cavity of an animal, including a human, wherein said dosage form comprises a matrix which contains one or more water-soluble polymers as base substances, and the active ingredient nicotine, said dosage form is characterized in that it is provided with spaces or cavities that are present in the polymeric matrix and whose contents differ from the matrix in terms of the state of aggregation, and wherein said dosage form does not contain a foam-stabilizing agent.

2. The dosage form as claimed in claim 1, characterized in that said dosage form is a sheet-like dosage form.

3. The dosage form as claimed in claim 1 oi claim 2, characterized in that said nicotine is present in the form of a salt.

4. The dosage form as claimed in claim 3, characterized in that said nicotine salt is nicotine bitartrate.

5. The dosage form as claimed in any one of claims I to 4, characterized in that said spaces or cavities are present in the matrix isolated from one another.

6. The dosage form as claimed in claim 5, characterized in that said spaces of cavities are present in the form of bubbles.

7. The dosage form as claimed in any one of claims 1 to 4, characterized in that said spaces or cavities are connected together.

8. The dosage form as claimed in claim 7, characterized in that said spaces or cavities are forming a channel system penetrating through the matrix.

9. The dosage form as claimed in any one of claims 1 to 8, characterized in that said spaces or cavities are filled with a gas or gas mixture.

10. The dosage form as claimed in claim 9, characterized in that said gas or gas mixture is air. Received at IPONZ on 29 April 2008 12

11.The dosage form as claimed in any one of claims 1 to 8, characterized in that said spaces or cavities are filled with a liquid or a liquid mixture which is immiscible with the matrix material.

12.The dosage form as claimed in claim 11 characterized in that the liquid or the liquid mixture contains said active ingredient.

13.The dosage form as claimed in any one of claims 1 to 12, characterized in that said spaces or cavities have a total volume, as a proportion of the total volume of the dosage form, of from 5 to 98%.

14.The dosage form as claimed in claim 13, characterized in that said total volume is from 50-80%.

15.The dosage form as claimed in any one or more of claims 1 to 11 or 13 or 14, characterized in that said spaces or cavities in the polymeric matrix are free of active ingredient in the state after production.

16.The dosage form as claimed in any one of claims 1 to 15, characterized in that said polymeric matrix represents a solidified foam.

17.The dosage form as claimed in any one of claims 1 to 16, characterized in that the surfaces of the dosage form have uneven or irregular shapes.

18.The dosage form as claimed in claim 17, characterized in that the surfaces of the dosage form have corrugated or relief-like shapes.

19.The dosage form as claimed in any one of claims 1 to 16, characterized in that the polymer content of the matrix consists of, one or more synthetic or partially synthetic polymers or of one or more natural biopolymers, which are film-forming and water-soluble, and which additionally contains one or more water-soluble polysaccharides of vegetable of microbial origin, and/or one or more proteins.

20.The dosage form as claimed in claim 19, characterized in that said one or more polymers are selected from the group which comprises cellulose derivatives, polyvinyl alcohol, polyacrylates and polyvinylpyrrolidone. Received at IPONZ on 29 April 2008 13

21. The dosage form as claimed in claim 20, wherein said cellulose derivatives are selected from: hydroxypropylmethylcellulose, hydroxymethyicellulose, carboxymethylcellulose, hydroxypropylcellulose and methylcellulose.

22. The dosage form as claimed in claim 19, characterized in that said one or more water-soluble polysaccharides are selected from the group which comprises, pullulan, xanthan, alginates, dextrans, agar-agar, pectins and carrageenan.

23. The dosage form as claimed in claim 19, characterized in that said one or more proteins are selected from the group which comprises, gelatin, casemates or other gel-forming proteins or protein hydrolysates. .

24. The dosage form as claimed in any one of claims 1 to 23, characterized in that it is in the form of a wafer.

25. The dosage form as claimed in any one of claims 1 to 24, characterized by having a thickness between 50 fim and 5 mm.

26. The dosage form as claimed in claim 25, wherein the thickness is between 0,5 and 1 mm.

27. The ddsage form as claimed in any one of claims 1 to 26, characterized in that said matrix and/or said spaces or cavities contain one or more pharmaceutically ac coptable excipients or additives.

28. The dosage form as claimed in claim 27, wherein said excipients or additives comprise one or more surfactants or gas-forming substances, moisturizers or humectants.

29. A process for the production of a sheet-like dosage form, which rapidly disintegrates or is soluble in an aqueous environment, for rapid release of the active ingredient nicotine in the oral cavity, in a body orifice or in a body cavity of an animal, including a human, wherein the dosage form comprises a matrix which contains one br more polymers as base substances, and further contains the active ingredient nicotine, the dosage form is provided with spaces or cavities which are present in the polymeric matrix and whose contents differ from the matrix in terms of the state of aggregation, and wherein the dosage form does not contain a foam-stabilizing agent, P005 Received at IPONZ on 29 April 2008 14 characterized by the following operational steps: a) preparation of a solution or dispersion which comprises at least one water-soluble film-forming polymer and the active ingredient, nicotine; b) foaming of the solution or dispersion by introducing gas or gas mixture or by chemical production of gas or by decompression of a dissolved gas; c) spreading of this solution or dispersion on a coating substrate; d) solidification of the cavity-containing film by drying and removal of the solvent.

30.A process for the production of a sheet-like dosage form, which rapidly disintegrates or is soluble in an aqueous environment, for rapid release of the active ingredient nicotine in the oral cavity, in a body orifice or in a body cavity of an aninial2 including a human, wherein the dosage form comprises a matrix which contains one or more polymers as base substances, and further contains the active ingredient nicotine, the dosage form is provided with spaces or cavities which are present in the polymeric matrix and whose contents differ from the matrix in terms of the state of aggregation, and wherein the dosage form does not contain a foam-stabilizing agent, characterized by the following operational steps: a) preparation of a solution or dispersion which comprises at least one water-soluble film-forming polymer and at least one active ingredient; b) addition of hydrophobic solvent which is immiscible with the solvent used to prepare said solution or dispersion, and preparation of an emulsion which contains the hydrophobic solvent in the form of finely dispersed droplets; c) spreading of this solution or dispersion on a coating substrate; d) solidification of the film with formation of cavities by drying and removal of the solvent.

31.A process for the production of a sheet-like dosage form, which rapidly diSihtegrateis or is soluble in an aqueous environment, for rapid release of the active ingredient nicotine in the oral cavity, in a body orifice or in a body cavity of an animal, including a human, wherein the dosage form comprises a matrix which contains one or more polymers as base substances, and further contains the active ingredient nicotine, the dosage form is provided with spaces or cavities which are present in the polymeric matrix and whose contents differ from the matrix in terms of the state of aggregation, and wherein the dosage form does not contain a foam-stabilizing agent Received at IPONZ on 29 April 2008 15 characterized by the following operational steps: a) preparation of a solution or dispersion which comprises at least one water-soluble film-forming polymer and the active ingredient nicotine; b) addition of an excipient or a combination of excipients capable of gas formation; c) spreading of this solution or dispersion on a coating substrate; d) solidification of the film with formation of cavities by drying and removal of the solvent. <

32.A process for the production of a sheet-like dosage form, which rapidly disintegrates or is soluble in an aqueous environment, for rapid release of the active ingredient nicotine in the oral cavity, in a body orifice or in a body cavity of an animal, including a human, wherein the dosage form comprises a matrix which contains one or more polymers as base substances, and further contains the active ingredient nicotine, the dosage form is provided with spaces or cavities which are present in the polymeric matrix and whose contents differ from the matrix in terms of the state of aggregation, and wherein the dosage form does not contain a foam-stabilizing a^cnt characterized by the following operational steps: a) preparation of a polymer-containing melt (hot melt) which comprises at least one water-soluble film-forming polymer and the active ingredient nicotine; b) foaming of the melt by introducing gas or gas mixture or by chemical production of gas or by decompression of a dissolved gas; c) spreading of the melt on a coating substrate; d) solidification of the film by cooling.

33.The process as claimed in one of any of claims 29 to 32, characterized in that steps c) and d) re replaced or modified by following steps c) and d): c) production of the polymer matrix in the form of a block, starting from the solution or dispersion or from the melt; d) cutting of the solidified block in order to Obtain sheet-like forms.

34.The process as claimed in any one of claims 29 to 33, characterized in that nicotine is added in the form of a salt.

35.The process as claimed in claim 34, wherein said salt is nicotine bitartrate. 16

36. The use of nicotine for the manufacture of a medicament according to the dosage form of any of claims 1 to 28 formulated for oral administration.

37. The use of nicotine for the manufacture of a medicament according to the dosage form of any of claims 1 to 28 formulated for rectal, vaginal or intranasal administration. sfc «j( sfi jJg